CL
TVTX icon

CSS LLC’s Travere Therapeutics TVTX Stock Holding History

CSS LLC’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,000
Closed -$121K – 1168
2022
Q2 		$121K Buy
+5,000
New +$126K ﹤0.01% 867
2022
Q1 		– Sell
-12,400
Closed -$385K – 1323
2021
Q4 		$385K Hold
12,400
– – 0.01% 737
2021
Q3 		$301K Buy
12,400
+300
+2% +$5.51K 0.01% 781
2021
Q2 		$177K Buy
12,100
+3,000
+33% +$59.2K 0.01% 864
2021
Q1 		$227K Buy
+9,100
New +$251K 0.01% 743

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CSS LLC's TVTX Position: Q2 2026 in Review

CSS LLC increased its Travere Therapeutics (TVTX) stake by 13% in Q2 2026, buying an estimated $44.3K and bringing the position to 8,470 shares worth $481K. The position accounts for 0.02% of the portfolio, ranked #563.

CSS LLC first reported a position in TVTX in Q1 2021 and has held it in 9 quarters since. The position peaked at $704K in Q2 2022. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • CSS LLC held 8,470 shares of Travere Therapeutics worth $481K as of Q2 2026.
  • CSS LLC bought 1,000 Travere Therapeutics shares in Q2 2026, an estimated $44.3K.
  • Travere Therapeutics made up 0.02% of CSS LLC's portfolio in Q2 2026, its #563 holding.
  • CSS LLC first reported a position in Travere Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • CSS LLC's Travere Therapeutics position peaked at $704K in Q2 2022.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on CSS LLC's 13F filing for Q2 2026, filed 14 Aug 2026.